To achieve excellence, our policy has always been Customer oriented. To meet specific needs, we have established several industrial collaborations. LabAnalysis Group was born from the union of several companies that incorporates over 40 years of consolidated and matured experience. The synergy allows us to offer complementary, up-to-date and effective services, always looking beyond the customer's expectations.
In order to protect patients and users of certain products, it is necessary to design study to assess the interaction between the released or migrated components into the pharmaceutical product and the possible health risk to the user.Read More
Nitrosamines represent one of the first risks of contamination in pharmaceutical products and basic active ingredients: listed as carcinogenic mutagens [...]Read More
Starting from 27th of March 2021 Reg. EU No. 1381/2019 – Transparency Regulation influences all applications for Regulated Products authorization, including food and feed additives, novel foods, food enzymes, flavorings and GMOs.Read More
An analysis conducted on the risk assessment allows companies and administrations to meet the increasingly high standards of safety in the FCM context. Indeed, [...]Read More
Medicines must be tested for the presence of nitrosamines before being released into the European Market, stated European Medicines Agency (EMA). LabAnalysis has developed [...]Read More
We are proud to be one of the 78 companies that have been awarded Welfare Champion 2020 by WelfareIndexPMI for the enhancement of the well-being of our employees. The event wa [...]Read More